• Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
SUGAR MGH Study: Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

Description: The SUGAR MGH Research Study will evaluate whether the different genes people inherit change the response to medications that are commonly used to treat type 2 diabetes, metformin and glipizide. As part of the study participants will be asked to take these medications and will also be given a sugar drink.

The study involves two visits to the research center one week apart, the first visit takes about 5 hours and the second about 3 hours. Blood will be drawn at both visits. Participants will receive monetary compensation, a parking voucher and a free meal for each completed visit.

Recruiting: We are seeking research volunteers over the age of 18 years who have diabetes but are not currently on diabetes medication, and/or who may be at risk for diabetes (for example, risk factors include high or “borderline-high” blood sugars, being overweight, having a history of gestational diabetes (diabetes during pregnancy), or having a first degree relative with type 2 diabetes).

Contact: Amelia Lanier at (617) 643-5419 or Marlene Fernandez at (617) 643-5417 or sugarmgh@partners.org
Institution  –  MGH - Massachusetts General Hospital, Boston, MA; BWH - Brigham and Women's Hospital, Boston, MA
Principal Investigator  – Jose Florez, MD, PhD
  
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Marlene Fernandez
Email  – sugarmgh@partners.org
Phone  – (617) 643-5417

About Type 2 Diabetes:
Type 2 diabetes is a metabolic disorder resulting from the body's inability to make enough, or to properly use, insulin. It used to be called non-insulin-dependent diabetes mellitus (NIDDM).
Without adequate production or utilization of insulin, the body cannot move blood sugar into the cells. It is a chronic disease that has no known cure. It is the most common type of diabetes, accounting for 90 to 95 percent of diabetes cases.